- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00282958
The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects diagnosed with subacute (2-6 months post-onset) bilateral cervical/ upper back pain will be recruited in this double-blind control study.
A total of 30 subjects with subacute cervical/upper back pain will be recruited. If patients are qualified as participants and agreed to participate in the study by signing the consent form, they will be randomized into either (A) control group (injection of normal saline injection) or (B) study group (injection of BOTOX). The initial history taking step will include medical history including medication and surgery history, duration of pain, pre-injection neck disability index (NDI) and visual analogue scale (VAS) for pain. VAS score will be collected for 4 weeks before injection to ensure stable VAS, otherwise medical records will be reviewed to ensure stable feature of pain. Short Form (SF) -36 Health Survey will be used to assess functional status, and the Beck Depression Inventory (BDI) will be applied to assess psychological aspect. Physical examination will be performed to determine the most tender cervical/ upper back muscles, and rule out operative condition. A simple swallowing test (3-oz water swallowing test) will be applied for dysphagia screening.
The patients will be maintained with routine, standardized physical therapy, oral medication, and stretch exercise after the injection. NDI, VAS, and SF-36 questionnaire will be re-collected at 1, 2, 3, 4, and 6 months after the injection session.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female 18 y/o or greater,
- Subacute bilateral cervical/ upper back pain, pain of longer than 2 months and shorter than 6 months duration,
- VAS pain score of 5 or greater for the cervical/ upper back pain for 4 week period before injection,
- If female or child bearing potential, concurrent use of a reliable method of contraception.
Exclusion Criteria:
- Known allergy or sensitivity to Botulinum toxin type A.
- Any medical condition that may put the subject at increased risk with exposure to BOTOX®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
- Use of aminoglycoside antibiotics, curare-like agents, or other agents that might interfere with neuromuscular function
- Pregnancy, breast feeding, or planned pregnancy
- Acute or operative pathology on cervical MRI
- History of treatment for gatro-esophageal reflux disease
- Abnormal finding on 3-oz water swallowing test on the initial screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
NDI, VAS, SF-36
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Elaine Date, MD, VA Palo Alto Health Care System
- Principal Investigator: Henry Lew, MD, Ph.D, VA Palo Alto Health Care System
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Back Pain
- Neck Pain
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- DAT0014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subacute Cervical Pain
-
University of TennesseeBlanchfield Army Community HospitalCompleted
-
Uppsala UniversityRegion Stockholm; Uppsala County Council, Sweden; National Social Insurance Board... and other collaboratorsCompleted
-
Texas Woman's UniversityTexas Physical Therapy AssociationCompletedLow Back Pain | Chronic Low Back Pain | Subacute Low Back PainUnited States
-
Palmer College of ChiropracticDepartment of Health and Human ServicesCompletedChronic Low Back Pain | Subacute Low Back PainUnited States
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsCompletedSubacute and Chronic Non-specific Low Back PainFrance
-
Kovacs FoundationCompletedChronic Nonspecific Low Back Pain | Subacute Nonspecific Low Back PainSpain
-
Assistance Publique - Hôpitaux de ParisCompletedSubacute or Chronic Low Back PainFrance
-
University of DeustoUniversity of the Basque Country (UPV/EHU); Osakidetza; Matia FoundationRecruitingCervical Pain | Cervical Radiculopathy | Cervical Radicular PainSpain
-
Xinqiao Hospital of ChongqingNot yet recruitingSubacute Thyroiditis
-
Xinqiao Hospital of ChongqingCompleted
Clinical Trials on Botulinum Toxin type a (Botox)
-
Medy-ToxCompletedCervical Dystonia
-
Daewoong Pharmaceutical Co. LTD.Completed
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingPancreatic CarcinomaUnited States
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
Brazilan Center for Studies in DermatologyCompletedWrinkles in Frontal AreaBrazil
-
HugelCompletedOveractive BladderKorea, Republic of
-
HugelCompletedCervical DystoniaKorea, Republic of
-
Seton Healthcare FamilyCompleted